This protocol addresses patients who have undergone resection of stage IIB or IIC melanoma. In this setting, post-operative systemic therapy is a recognised part of management, and specific agents are recommended for eligible patients.
Adjuvant immunotherapy is recommended for patients following resection at these stages. The full protocol specifies which agents apply, the selection criteria between them, and all relevant scheduling details — none of which are reproduced here in full.